Theravance Biopharma Inc (TBPH)

Theravance Biopharma's stock has increased significantly, with an 82.04% increase in the past six months. Key events include strong Q3 2025 financial results, with EPS surpassing forecasts and YUPELRI net sales reaching an all-time high. Management is confident about the upcoming Cypress trial data readout for ampreloxetine in Q1 2026. The stock has received "Buy" ratings from research firms.

Demand for Theravance Biopharma's products, particularly YUPELRI, is impacted by seasonality, with the first quarter typically experiencing lower demand. Despite this, YUPELRI has shown strong growth, with net sales increasing by 15% year-over-year in Q3 2025 and hospital channel doses increasing by 29% year-over-year. Customer demand for YUPELRI grew 6% year-over-year in Q3 2025.

Theravance Biopharma, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing organ-selective medicines, particularly for specialty respiratory and neurologic diseases. Their portfolio includes commercialized products like YUPELRI for COPD and a pipeline of investigational therapies such as Ampreloxetine, Izencitinib and Nezulcitinib. The company also has strategic collaborations with various pharmaceutical companies.

Theravance Biopharma operates through U.S. and Europe geographical segments, with products commercialized in the United States, Europe, and Asia. Founded in July 2013, the company is headquartered in George Town, Cayman Islands, and has operations in South San Francisco, California.

Theravance Biopharma maintains a positive brand reputation, reflected by analyst ratings and market performance. The company has a consensus "Strong Buy" rating from analysts, with an average rating score of 1.75. MarketBeat's MarketRank™ score places Theravance Biopharma higher than 76% of evaluated companies.

Theravance Biopharma has substantial institutional ownership, with 305 institutional owners and shareholders holding 51,995,385 shares, accounting for 99.10% of the stock. Major institutional owners include Madison Avenue Partners, LP, and Weiss Asset Management LP. In the past three months, company insiders have sold $582,506.00 in company stock, with insiders holding 6.90% of the stock.